Home The Word Brain My Amedeo FAQ Privacy About   


Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.


  Lung Cancer

  Free Subscription


Articles published in Lancet

Retrieve available abstracts of 25 articles:
HTML format



Single Articles


    November 2025
  1. AERTS JG, Dammeijer F
    Progress in outcomes for patients with metastatic squamous non-small-cell lung cancer.
    Lancet. 2025;406:2034-2035.
    PubMed    


    October 2025
  2. CHEN Z, Yang F, Jiang Z, Sun L, et al
    Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy as first-line treatment for advanced squamous non-small-cell lung cancer (HARMONi-6): a randomised, double-blind, phase 3 trial.
    Lancet. 2025 Oct 19:S0140-6736(25)01848-3. doi: 10.1016/S0140-6736(25)01848.
    PubMed     Abstract available


    September 2025
  3. PRAMESH CS, Kelly K, Hunter DJ, Coelho Wisdom V, et al
    The IASLC-Lancet Commission: a transformative global approach to lung cancer.
    Lancet. 2025 Sep 7:S0140-6736(25)01719-2. doi: 10.1016/S0140-6736(25)01719.
    PubMed    


    August 2025
  4. BARLESI F, Yao W, Duruisseaux M, Doucet L, et al
    Adagrasib versus docetaxel in KRAS(G12C)-mutated non-small-cell lung cancer (KRYSTAL-12): a randomised, open-label, phase 3 trial.
    Lancet. 2025;406:615-626.
    PubMed     Abstract available


  5. SMIT EF, Dingemans AC
    Adagrasib for KRAS(G12C) mutated advanced non-small-cell lung cancer.
    Lancet. 2025;406:576-577.
    PubMed    


    June 2025
  6. CHOUDHURY NJ, Garassino MC
    Lurbinectedin with atezolizumab maintenance therapy in extensive-stage small-cell lung cancer.
    Lancet. 2025;405:2104-2106.
    PubMed    


    May 2025
  7. PAZ-ARES L, Borghaei H, Liu SV, Peters S, et al
    Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial.
    Lancet. 2025 May 30:S0140-6736(25)01011-6. doi: 10.1016/S0140-6736(25)01011.
    PubMed     Abstract available


    March 2025
  8. XIONG A, Wang L, Chen J, Wu L, et al
    Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China.
    Lancet. 2025;405:839-849.
    PubMed     Abstract available


    September 2024
  9. SPICER JD, Garassino MC, Wakelee H, Liberman M, et al
    Neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab compared with neoadjuvant chemotherapy alone in patients with early-stage non-small-cell lung cancer (KEYNOTE-671): a randomised, double-blind, placebo-controlled, phase 3
    Lancet. 2024 Sep 12:S0140-6736(24)01756-2. doi: 10.1016/S0140-6736(24)01756.
    PubMed     Abstract available


  10. PRESLEY CJ, Owen DH
    Improved survival for patients with lung cancer treated with perioperative immunotherapy.
    Lancet. 2024 Sep 12:S0140-6736(24)01920-2. doi: 10.1016/S0140-6736(24)01920.
    PubMed    


    August 2024
  11. MEYER ML, Fitzgerald BG, Paz-Ares L, Cappuzzo F, et al
    New promises and challenges in the treatment of advanced non-small-cell lung cancer.
    Lancet. 2024 Aug 6:S0140-6736(24)01029-8. doi: 10.1016/S0140-6736(24)01029.
    PubMed     Abstract available


    July 2024
  12. CHANG JY, Verma V, Heymach JV
    Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer - Authors' reply.
    Lancet. 2024;404:241-242.
    PubMed    


  13. HINDIE E
    Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer.
    Lancet. 2024;404:241.
    PubMed    


  14. JIANG L, Yu J, Meng X
    Stereotactic ablative radiotherapy and immunotherapy for early-stage lung cancer.
    Lancet. 2024;404:240-241.
    PubMed    


    June 2024
  15. THE LANCET
    Lung cancer treatment: 20 years of progress.
    Lancet. 2024;403:2663.
    PubMed    


    May 2024
  16. GIJTENBEEK RG, Noordhof AL, Asmara OD, Groen HJ, et al
    Immunotherapy in frail non-small-cell lung cancer patients.
    Lancet. 2024;403:1986.
    PubMed    


    March 2024
  17. MUROYA D, Morimitsu Y, Nakamura K, Hayashi K, et al
    Hidden metastatic lung tumour diagnosed by AI.
    Lancet. 2024;403:1290.
    PubMed    


  18. EDERHY S, Cadranel J, Granger C, Hammoudi N, et al
    Investigation of endocarditis finds advanced lung adenocarcinoma: both resolve after tyrosine kinase inhibitor treatment.
    Lancet. 2024;403:860-861.
    PubMed    


    January 2024
  19. PAZ-ARES L, Mehta B, Wang Y, Obiozor C, et al
    Sotorasib in KRAS(G12C) mutated lung cancer - Authors' reply.
    Lancet. 2024;403:145-146.
    PubMed    


  20. OLIVIER T, Prasad V
    Sotorasib in KRAS(G12C) mutated lung cancer.
    Lancet. 2024;403:145.
    PubMed    


  21. HANNA GG, McDonald F
    SBRT for oligoprogressive disease: using the evidence to maximise the benefits.
    Lancet. 2024;403:122-124.
    PubMed    


    December 2023
  22. CHU Q, Perrone F, Greillier L, Tu W, et al
    Pembrolizumab plus chemotherapy versus chemotherapy in untreated advanced pleural mesothelioma in Canada, Italy, and France: a phase 3, open-label, randomised controlled trial.
    Lancet. 2023;402:2295-2306.
    PubMed     Abstract available


  23. LEE YCG
    Pembrolizumab plus chemotherapy for pleural mesothelioma.
    Lancet. 2023;402:2266-2267.
    PubMed    


  24. TSAI CJ, Yang JT, Shaverdian N, Patel J, et al
    Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomi
    Lancet. 2023 Dec 14:S0140-6736(23)01857-3. doi: 10.1016/S0140-6736(23)01857.
    PubMed     Abstract available


    November 2023
  25. SALMAN M, Fernandez Crespo R, Judah G
    Impact of messaging informed by behavioural science on uptake of targeted lung health checks: a service evaluation.
    Lancet. 2023;402 Suppl 1:S82.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.